| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
4,356 |
3,642 |
$16.19M |
| J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
2,818 |
2,496 |
$9.03M |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
204 |
189 |
$601K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,939 |
5,808 |
$204K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,824 |
3,465 |
$200K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,138 |
3,457 |
$137K |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
50 |
49 |
$112K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,623 |
1,619 |
$105K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,560 |
3,523 |
$79K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,062 |
968 |
$20K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
470 |
429 |
$9K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
118 |
118 |
$6K |
| 96401 |
|
418 |
360 |
$6K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
226 |
223 |
$4K |
| 20610 |
|
45 |
43 |
$1K |